Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
4th-generation EGFR inhibitor (Acerand Therapeutics)
- Development stage
- Preclinical
- Lead developer
- Acerand Therapeutics
- Modality
- Small Molecules
01
Overview
Acerand Therapeutics' 4th-generation EGFR inhibitor is a small molecule therapeutic designed to target Epidermal Growth Factor Receptor (EGFR) mutations, specifically the C797S double mutation. This mutation is a primary driver of resistance to third-generation EGFR tyrosine kinase inhibitors (TKIs) such as osimertinib in patients with non-small cell lung cancer (NSCLC). By selectively inhibiting these double mutants, the drug aims to restore therapeutic efficacy and provide a more durable response for patients who have progressed on current standard-of-care therapies. The program is currently in the discovery stage of development for the treatment of solid tumors.
- Other names
- EGFR (C797S double mutants) inhibitor
02
Targets
EGFR T790M/C797S (Epidermal growth factor receptor (EGFR) T790M/C797S mutant)EGFR T790M (Epidermal growth factor receptor T790M mutant)
Beyond the preview
Go deeper on 4th-generation EGFR inhibitor (Acerand Therapeutics).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 4th-generation EGFR inhibitor (Acerand Therapeutics).